Answers are grounded in this paper and cite their sources.
Background/Aims: To investigate whether the peroxisome proliferator-activated receptor-γ (PPAR-γ) Pro12Ala and the PPAR-γ coactivator-1α (PGC-1α) Gly482Ser polymorphisms were associated with polycystic ovary syndrome (PCOS). Methods: Genetic analyses of the PPAR-γ Pro12Ala and the PGC-1α Gly482Ser polymorphisms were performed in 184 patients with PCOS and 256 controls. Hormone levels, biochemical and clinical features were analyzed according to these polymorphisms. Results: Neither the PPAR-γPro12Ala nor the PGC-1α Gly482Ser polymorphism showed significant differences in genotypic distribution between women with PCOS and controls. In PCOS patients, women with the non-Pro/Pro genotypes of the PPAR-γ Pro12Ala polymorphism showed statistically significantly higher HDL levels than those with the Pro/Pro genotype (p = 0.002). PCOS patients who had the Ser/Ser genotype of the PGC-1α Gly482Ser polymorphism had significantly higher levels of postprandial 2-hour insulin than those with the Gly/Ser genotype (p = 0.045). Conclusions: Neither the PPAR-γPro12Ala nor the PGC-1α Gly482Ser polymorphism were supposed to be susceptible genes in PCOS. However, in PCOS patients, the PPAR-γPro12Ala and the PGC-1α Gly482Ser polymorphism may modulate the concentrations of serum HDL levels and postprandial 2-hour insulin level, respectively.
No takes yet. Share an insight, caveat, or question.
Chae et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: